agilon Health Q1 2026: Margin Strengthening Amid Membership Shifts and a New CEO at the Helm

nyse ticker AGL found a curious mix in its first quarter of 2026: revenue declined year over year, yet margins expanded and management nudged up the revenue forecast for the full year. In a press release styled with the polish of a Wdesk-era deck, agilon health, inc. reported results for the quarter ended March 31, 2026, and announced Tim O’Rourke as the new chief executive officer. The beats and misses aren’t measured in a single line item—this is a story about earnings quality, trajectory, and the strategic scaffolding around a care model that auctions for deeper payor alignment and better outcomes.

What happened in the quarter

Revenue: $1.42 billion for the first quarter 2026, down 7% year over year from $1.53 billion in Q1 2025.
Membership and mix: Total members on the agilon platform fell to 536,000 as of March 31, 2026, consisting of 426,000 Medicare Advantage members and 110,000 ACO model beneficiaries. The company attributes the decline to previously disclosed market exits and payor exits, a disciplined approach to contracting aimed at profitability.
Gross profit: $65 million in Q1 2026, up from $51 million in Q1 2025.
Net income: $49 million in Q1 2026 versus $12 million in Q1 2025.
Medical margin: $149 million in Q1 2026, with commentary noting cost trends for Medicare Advantage members reserved at 7.4%.
Adjusted EBITDA: $54 million in Q1 2026, up from $21 million in Q1 2025, reflecting the combined effects of the revenue mix, cost discipline, and performance in ACO REACH initiatives.
Guidance: The company raised its full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA, signaling confidence in execution despite a revenue headwind from membership declines.

Leadership change and strategic context

The press release names Tim O’Rourke as chief executive officer, described as bringing more than 25 years of healthcare leadership. The stated aim is to sharpen execution with faster pull-through from action to outcome and to deliver greater value for all stakeholders. Management underscored ongoing investments in data and technology, clinical execution, and operating discipline as levers to drive margin expansion and predictability in outcomes. The tone suggests a multi-year plan to strengthen the Total Care Model with expanded clinical pathways, improved quality, and deeper payer alignment.

What it means for EPS and the earnings narrative

While the release emphasizes revenue, margins, and Adjusted EBITDA rather than the classic GAAP EPS figure, investors will be watching how per-share metrics come together as 2026 unfolds. The absence of an explicit EPS figure in the press release doesn’t erase the relevance of EPS-related questions: will the EPS trajectory align with the improved revenue forecast and higher EBITDA? For now, the market will likely test the implied EPS path against the elevated guidance, staying alert to any earnings surprise—positive or negative—versus consensus expectations. The company’s decision to raise guidance could be read as management signaling that the next few quarters may produce better-than-expected per-share results, even if top-line growth remains constrained by membership dynamics.

Strategic implications for peers and the sector

agilon’s quarter places a spotlight on the tension between member growth and profitability in value-based care platforms. The combination of a shrinking member base with rising profitability hints at a pivot from volume to value—one that may resonate with peers facing similar market exits and payor consolidation. For sector peers, the message is twofold: discipline in contracting to protect margins matters, and leadership stability—plus a clear growth path around data, technology, and payer relationships—remains a competitive differentiator. In the near term, investors may look to whether agilon’s revised revenue forecast and higher EBITDA translate into stronger cash generation and healthier earnings per share in coming quarters, a test for the resilience of the care-model strategy across the industry.

What to watch next

Revenue forecast trajectory: Will the updated guidance prove durable as the company navigates member exits and market exits?
EPS trajectory: How will GAAP and/or adjusted earnings per share track against expectations, and will there be any earnings surprises in subsequent quarters?
Membership dynamics: Do the exits represent a temporary rebalancing or a longer-term shift in the platform’s addressable market?
Strategic execution: How effectively Tim O’Rourke can translate the investments in data, clinical pathways, and payer alignment into measurable improvements in margins and growth?

Bottom line

agilon health is delivering a narrative of margin progression under leadership transition, with a cautious eye on membership headwinds. The Q1 results show meaningful profitability gains—net income and Adjusted EBITDA both up meaningfully year over year—while revenue contractures remind us that growth remains a work in progress. The raised revenue forecast and other guidance tweaks imply management’s confidence in a steadier path in 2026, but the payoff in EPS terms will hinge on how quickly the platform can stabilize membership, translate that stability into price and contract economics, and sustain payer alignment. For now, AGL’s quarter reads as a deliberate, perhaps even surgical, shift toward a leaner, more predictable care-model enterprise—one that could set the pace for peers navigating a challenging but potentially rewarding healthcare landscape.